Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis
Recruiting
Observational Study
Prurigo Nodularis (PN)
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 40 (estimated)
- Sponsor
- UMC Utrecht · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted treatment.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adult patients with moderate-to-severe prurigo nodularis starting dupilumab treatment
Exclusion Criteria:
* Unwilling to participate in the BioDay registry
* (For translational endpoints only) Unwilling to participate in UMC Utrecht Biobank
Contacts